Opinion|Videos|November 17, 2026

HIV Adherence vs Regimen Change: Lived Experience and Hidden Drug Interactions

Distinguishing an adherence barrier from a true need for a new regimen starts with asking why, and a single overlooked interaction can explain persistent viremia in an otherwise adherent patient.

This episode, "HIV Adherence vs Regimen Change: Lived Experience and Hidden Drug Interactions," features the panel examining how to tell whether a patient needs a new regimen or better support.

Dr. Astle says his first question is always why a change is being considered. If viral suppression is slipping because a patient cannot reach the pharmacy or struggles to remember daily pills, adherence support is the right tool. If the problem is side effects, injection tolerability, or a change in renal function, a regimen change is warranted. Adherence barriers can be addressed, but those clinical factors cannot. Dr. Madison adds that lived experience matters, including child care, food insecurity, and housing instability. A regimen with a food requirement is a poor fit for someone unsure when their next meal will come. Dr. Astle notes that pill bottles at home can risk disclosure of HIV status or be stolen when storage is not secure. Dr. Madison argues that simply telling patients to take pills daily has been shown not to work.

Dr. Durham then addresses the unmet needs he still sees. Modern regimens achieve near-universal suppression, but only when patients actually take them. Adherence extends to injectables as well. He describes a patient on long-acting cabotegravir/rilpivirine who routinely reschedules, sometimes by a week. Drug interactions also remain relevant, even though current regimens carry fewer than older ones. He illustrates the cation interaction with integrase inhibitors through a patient case. She had no resistance, seemed highly adherent, and avoided milk, yet her viral load would not become undetectable. After an hour-and-a-half appointment, the team discovered she took her dose with calcium-fortified orange juice. She had not connected the calcium in juice with the calcium in milk. Dr. Durham says such nuances are exactly what pharmacists are positioned to uncover. Dr. Burkhart adds that frequent touch points build trust. Reassuring patients that a missed dose is fixable reduces defensiveness about adherence.

The next episode in this series, "Polypharmacy in Aging HIV Patients and Evaluating New Antiretroviral Agents," features Dr. Burkhart on polypharmacy in older adults and Dr. Astle on judging true innovation.

Funding supported by Gilead. Content independently developed by Pharmacy Times.


Related to this article